Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8186
Title: | Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer | Authors: | Akça, Hakan Demiray, Aydın Yaren, Arzu Bir, Ferda Köseler, Aylin Iwakawa, R. Bağcı, Gülseren |
Keywords: | EGFR Mutations NSCLC Serum DNA Turkish DNA epidermal growth factor receptor paraffin adult aged article cancer staging controlled study DNA determination DNA isolation DNA sequence epidermal growth factor receptor gene female gene mutation genetic association human human tissue lung adenocarcinoma lung non small cell cancer lung squamous cell carcinoma major clinical study male mutation rate mutational analysis point mutation priority journal pyrosequencing single nucleotide polymorphism tissue section Adenocarcinoma Aged Base Sequence Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell DNA, Neoplasm Female Humans Logistic Models Lung Neoplasms Male Middle Aged Multivariate Analysis Mutation Mutation Rate Mutation, Missense Neoplasm Staging Neoplastic Cells, Circulating Receptor, Epidermal Growth Factor Sequence Analysis, DNA Sequence Deletion |
Abstract: | Mutations in the EGFR gene are critical determinants of treatment with EGFR tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) patients. DNA isolation from tumor samples usually requires surgery; therefore, we wanted to isolate DNA from circulating tumor cells by using the serum of NSCLC patients. This protocol was recently published. DNA was isolated from the serum of 52 Turkish NSCLC patients and their EGFR mutation status was examined by pyrosequencing. EGFR mutations were detected in 25 of the 52 patients (48.1%): 17 patients with delE746-A750, 2 with delE747-A750insP, and 6 with L858R. All mutations detected by pyrosequencing were confirmed by dideoxy sequencing, and the presence of the same mutations in the tumors was verified by using paraffin embedded tissues of all the patients. Mutations were detected more frequently in adenocarcinomas (24 of 36, 66.7%) than in squamous cell carcinomas (1 of 16, 6.3%) (. P < 0.001). These results confirm the utility of serum DNA and pyrosequencing for the detection of EGFR mutations in patients with advanced NSCLC. © 2013 . | URI: | https://hdl.handle.net/11499/8186 https://doi.org/10.1016/j.cancergen.2013.01.005 |
ISSN: | 2210-7762 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
39
checked on Nov 30, 2024
WEB OF SCIENCETM
Citations
40
checked on Dec 1, 2024
Page view(s)
62
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.